<DOC>
	<DOCNO>NCT01445392</DOCNO>
	<brief_summary>Background : Standard therapy mesothelioma combination drug pemetrexed cisplatin . However , benefit treatment limit , treat patient disease continue worsen . SS1 ( dsFV ) PE38 genetically engineer drug . It contain antibody bind certain protein mesothelioma cell toxin ( type poison ) make product bacterium call Pseudomonas aeruginosa . It hop antibody attach cancer cell , allow toxin enter kill cell . Objectives : To find SS1 ( dsFV ) PE38 , together pemetrexed cisplatin safe tolerable patient mesothelioma . To determine maximum tolerate dose SS1 ( dsFV ) PE38 ( high dose cause unacceptable side effect ) . To see SS1 ( dsFV ) PE38 give pemetrexed cisplatin effect patient tumor . To learn body break SS1 ( dsFV ) PE38 . Eligibility : Patients 18 year age older epithelial pleural mesothelioma whose disease cure surgery , prior treatment chemotherapy . Design : Treatment pemetrexed , cisplatin SS1 ( dsFV ) PE38 two 21-day cycle follow : - Day 1 - Intravenous ( vein ) infusion pemetrexed cisplatin . - Days 1 2 - Intravenous solution prevent dehydration might occur SS1 ( dsFV ) PE38 . - Days 1 , 3 5 Intravenous infusion SS1 ( dsFV ) PE38 . Small group ( 3 6 ) patient give SS1 ( dsFV ) PE38 certain dose level . If first group experience significant side effect , next group high dose . This continue succeed group maximum tolerate study dose ( high dose patient give safely ) determine . Continuing standard treatment additional cycle pemetrexed cisplatin . Evaluations treatment period : - Physical examination , include vital sign body weight check , pregnancy test woman become pregnant . - Questions medication side effect . - Blood urine test . - Disease evaluation CT , chest X-ray , possibly PET scan , lung function test , pulse oximetry , performance daily activity quality-of-life questionnaire . Post-treatment evaluation : - Clinic visit month 1 , 3 , 6 , 12 , 15 , 18 21 physical examination disease assessment . - End-of-study visit blood test , vital sign weight measurement , disease assessment , electrocardiogram , pregnancy test woman become pregnant</brief_summary>
	<brief_title>SS1 ( dsFV ) PE38 Plus Pemetrexed Cisplatin Treat Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>Background : SS1P ( dsFv ) PE38 , recombinant immunotoxin target tumor antigen mesothelin highly express malignant mesothelioma . The maximum tolerated dose ( MTD ) SS1 dsFv establish phase I study . Combination therapy pemetrexed plus cisplatin standard first line therapy malignant mesothelioma , result median overall survival 12.1 month . Combination SS1 ( dsFv ) PE38 pemetrexed plus cisplatin could result improved outcome patient mesothelioma . Objectives : To determine MTD SS1 ( dsFv ) PE38 safely administer combination pemetrexed plus cisplatin patient mesothelioma . To characterize toxicity profile SS1 ( dsFv ) PE38 . To study pharmacokinetics SS1 ( dsFv ) PE388 . To observe anti-tumor activity , SS1 ( dsFv ) PE38 combination pemetrexed plus cisplatin . Eligibility : Subjects histologically confirm epithelial pleural mesothelioma . No prior radiotherapy ( except palliative localized radiotherapy ) , systemic chemotherapy biologic therapy pleural mesothelioma . Design : This phase I dose-escalation study SS1 ( dsFv ) PE38 combination pemetrexed plus cisplatin . The dose pemetrexed plus cisplatin standard dose approve malignant mesothelioma . The dose SS1 ( dsFv ) PE38 escalate find safe dose combination pemetrexed plus cisplatin . SS1 ( dsFv ) PE38 administer concurrently pemetrexed plus cisplatin cycle one two , subject receive additional cycle pemetrexed cisplatin per standard practice . Patients assessed response every 6 week . An additional Single Cycle SS1 ( dsFv ) PE38 Cohort involve 16 patient receive SS1 ( dsFv ) PE38 administer four five dos first cycle concurrently pemetrexed cisplatin ; subject cohort receive additional cycle pemetrexed cisplatin per standard practice</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects must meet follow criterion eligible participate study : Subjects must histologically confirm epithelial biphasic pleural mesothelioma amenable potentially curative surgical resection . However , patient biphasic tumor predominantly sarcomatoid component exclude . Measurable disease Subjects must great equal 18 year old Karnofsky Performance Status ( KPS ) great equal 70 Life expectancy great 3 month , assess principal investigator . Adequate organ function : Hepatic function : serum transaminase ( either ALT AST ) bilirubin , less equal Grade 1 , unless due cancer Gilbert disease ; le equal Grade 2 , due cancer Renal function : serum creatinine clearance great equal 60mL/min estimate CockroftGault formula . Bone marrow function : ANC least 1,500/mm ( 3 ) , Platelet count least 100,000/mm ( 3 ) Pulmonary Function : FEV ( 1 ) great equal 50 percent predict value ( postpleural drainage bronchodilation indicate ) Must able understand sign inform consent Female male subject agree use approve method contraception study EXCLUSION CRITERIA : Subjects must pregnant breast feed Prior radiotherapy ( except palliative extrathoracic localize radiotherapy ) biologic therapy malignant pleural mesothelioma within 4 week Prior systemic chemotherapy malignant pleural mesothelioma Documented ongoing central nervous system involvement malignant disease ( history CNS involvement exclusion criterion CNS metastases adequately treat ( radiation surgical resection ) subject free symptom 3 month steroid ) . Clinically significant heart disease ( New York Heart Association Class III IV ) Active bacterial fungal infection . Baseline coagulopathy great equal Grade 3 unless due anticoagulant therapy Surgery pleurodesis within 2 week HIV positive serology ( due increase risk severe infection unknown interaction SS1 ( dsFv ) PE38 antiretroviral drug ) Hepatitis B surface antigen positivity Subjects ( nonmesothelioma ) cancer meet eligibility criterion le 5 year diseasefree survival consider casebycase basis Uncontrolled , symptomatic , intercurrent illness include limited : infection require systemic antibiotic , unstable angina pectoris , cardiac arrhythmia , psychiatric illness , social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 27, 2016</verification_date>
	<keyword>Recombinant Immunotoxin</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Pseudomonas Exotoxin</keyword>
	<keyword>Targeted Therapy</keyword>
	<keyword>Pleural Mesothelioma</keyword>
	<keyword>Mesothelioma</keyword>
	<keyword>Epithelial Pleural Mesothelioma</keyword>
</DOC>